Summary
In the acute phase of myocardial infarction it is recognized that serum disopyramide concentrations may be lower than expected. This has generally been attributed to reduced oral bioavailability.
This report describes data obtained routinely from 6 patients with acute myocardial infarction and cardiac dysrhythmias treated initially with intravenous disopyramide. Serum disopyramide concentrations were consistently lower than expected, on average by 2.6 µg/ml. This was interpreted as being due to relatively high drug clearance, calculated as 6.7±1.5 l/h, compared to expected values of 3–4 l/h.
Dosage schedules determined on the basis of the acute phase pharmacokinetics subsequently produced higher than predicted concentrations at later times on average by 2.8 µg/ml. Clearance at this time was calculated to be 3.1±0.6 l/h.
Thus even with intravenous disopyramide therapy there are problems with changing pharmacokinetic parameters after myocardial infarction.
This is a preview of subscription content, log in via an institution to check access.
References
Bryson SM, Cairns CJ, Whiting B (1982) Disopyramide pharmacokinetics during recovery from myocardial infarction. Br J Clin Pharmacol 13: 417–421
Caplin JL, Johnston A, Hamer J, Camm AJ (1985) The acute changes in serum binding of disopyramide and flecainide after myocardial infarction. Eur J Clin Pharmacol 28: 253–255
David BM, Ilett KF, Whitford EG, Stenhouse NS (1983) Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction. Br J Clin Pharmacol 15: 435–441
Ilett KF, Madsen BW, Woods JD (1979) Disopyramide kinetics in patients with acute myocardial infarction. Clin Pharmacol Ther 26: 1–7
Kelman AW, Whiting B, Bryson SM (1982) OPT: A package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol 14: 247–256
Kumana CR, Rambihar VS, Tanser PN, Cairns JA, Gupta RN, Wildeman RA, Johnston M, Johnson AL, Gent M (1982) A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. Br J Clin Pharmacol 14: 519–527
Pentikäinen PJ, Huikuri H, Jounela AJ, Wilen G (1985) Disopyramide pharmacokinetics in patients with acute myocardial infarction. Eur J Clin Pharmacol 28: 45–51
Sheiner LB, Beal S, Rosenberg B, Marathe VV (1979) Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26: 294–305
Shen DD, Cunningham JL, Shudo I, Azarnoff DL (1980) Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos 1: 133–140
Sullivan J (1981) Unusual dosage of disopyramide. Med J Aust 2: 455
Ward JW, Kinghorn GR (1976) The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens. J Int Med Res 4 [1]: 49–53
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elliott, H.L., Thomson, A.H. & Bryson, S.M. Disopyramide in acute myocardial infarction: Problems with changing pharmacokinetics. Eur J Clin Pharmacol 30, 345–347 (1986). https://doi.org/10.1007/BF00541541
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541541